The Food and Drug Administration has approved a new oral medication that is significantly extending survival times for patients with advanced pancreatic cancer, marking a breakthrough in treatment for one of the most lethal cancer diagnoses.
The drug, daraxonrasib, manufactured by Revolution Medicine, received FDA approval following an expedited 35-day review. Clinical trial results demonstrated that patients who had already undergone chemotherapy lived more than 13 months on the medication, compared to 7 months without it—effectively doubling their survival time.
Pancreatic cancer carries one of the bleakest prognoses in oncology. Only 3 percent of patients survive beyond five years following diagnosis, a threshold commonly used to define cancer survival. The disease typically necessitates intensive chemotherapy regimens, and options have been severely limited for patients whose cancer persists after initial treatment.
The phase 3 clinical trial results that informed the FDA decision were presented in May at the annual meeting of the American Society of Clinical Oncology in Chicago. According to the New York Times, the announcement prompted attending physicians and scientists to rise in applause, with some moved to tears by the findings.
"I have not seen anything like that before in trials we have run in pancreatic cancer," Dr. Brian Wolpin of the Dana-Farber Cancer Institute in Boston, who led the study, told the New York Times. "I just kept repeating, 'Wow.'"
The medication operates by targeting a protein called KRAS, which pancreatic cancer cells require for survival. For decades, pharmaceutical researchers considered KRAS an impossible target due to its smooth molecular surface, which offered no obvious point of attachment for drugs. Daraxonrasib overcomes this obstacle by binding other molecules together in a configuration that allows the compound to attach to and inhibit KRAS, preventing it from reaching tumor cells.
The approval represents more than a single treatment option. It validates an entire research approach that could benefit patients with other cancers that depend on KRAS, including colon and lung cancer. The New York Times reported that dozens of KRAS-inhibiting medications are currently under investigation, being tested both as standalone treatments and in combination with chemotherapy and immunotherapy.
While the drug primarily extends survival, some patients have experienced remarkable results. One man in his seventies enrolled in the daraxonrasib clinical trial in 2022 after his cancer had spread to his lymph nodes. The medication reduced his tumors to the point where they are no longer visible on scans, and he remains alive today.
The FDA approval covers use of daraxonrasib after chemotherapy has failed to control the disease. The drug is administered as a twice-daily pill and is largely covered by insurance plans. Researchers are now evaluating whether the medication might prove effective when administered at earlier stages of pancreatic cancer treatment, potentially before chemotherapy or in combination with initial therapies.
The development offers tangible hope for patients facing a diagnosis that has historically left few treatment pathways once initial interventions prove unsuccessful. The rapid FDA review and approval process reflects the urgent medical need for effective pancreatic cancer treatments and the strength of the clinical trial evidence supporting the drug's efficacy.
